Drugs to raise HDL failed miserably in clinical trials for heart disease.
But they may have value in treating Alzheimer’s.
Quoted:
“This was from a prespecified secondary analysis of data from a cardiovascular-focused trial of obicetrapib called BROADWAY, primary results from which were reported in May. The drug works by blocking conversion of high-density lipoprotein (HDL) cholesterol into the low-density form (LDL). CETP inhibitors were all the rage a few years ago as a novel approach to cholesterol management, but poor results with the first wave of candidates didn't meet expectations.”
“But research on the interplay of cholesterol metabolism and Alzheimer's disease led the company to keep an eye on obicetrapib's effects on Alzheimer's disease biomarkers. "Lipid dysregulation is very important for Alzheimer's disease, it's an important risk factor, especially with APOE4," he told attendees. "Obicetrapib actually has the ability to significantly change p-tau progression over time as compared with placebo."
“The investigators' belief, Scheltens said, is that these effects are not a consequence of diminished HDL-LDL conversion, but rather some type of direct action on Alzheimer's pathology.”
#hdlHD #alzheimersHD #dementiaHD #obicetrapibHD #cetpinhibitorHD #broadwayHD #ptau217HD #apoe4HD


